Spectral Medical Inc - Corporate Presentation

Financial Advisors, Investment Advisors, Analysts, and Institutional Portfolio Managers are cordially invited to attend a presentation for: Corporate Presentation In Montréal
Jun 6, 2019 - 12:00 PM EDT
Hôtel Omni Mont-Royal (Salon Été) - 1050, rue Sherbrooke ouest , Montréal, Québec

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 150,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year. Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information please visit www.spectraldx.com.